-
-
WE Volunteer | SDG Popularization Month
2023-08-04
The fifth themed month of WE Volunteer——July’s “SDG Popularization Month” comes to a close! In response to the current challenges all around the world, the SDGs (Sustainable Development Goals) were adopted by United Nations in 2015 calling for action by all countries to promote prosperity while protecting the planet. Over the past month, we invited Fosun ecosystem partners to
-
-
Fosun Tourism Group Issues Positive Profit Alert Profit in the 1H2023 is expected to be not less than RMB430 million
2023-08-03
On 3 August 2023, Fosun Tourism Group(“Fosun Tourism”or the“Group”, Hong Kong Stock Exchange Stock Code: 1992) issued a profit alert announcement for the first half of 2023. Benefiting from the relaxation of travel restrictions around the world and the effective implementation of the Group’s strategy, all business sectors under Fosun Tourism Group have continued their
-
-
Club Med Releases a New Urban Resort Product Line, Club Med Urban Oasis, and its First Resort, Xianlin Nanjing Resort is About to Open Soon
2023-07-31
Club Med, the world’s leading provider of premium all-inclusive holidays under Fosun Tourism Group, announced the launch of a new upscale urban vacation product line, Club Med Urban Oasis, to embrace "urban vacation" lifestyle trend of nowadays. The selection of project location for “Urban Oasis” will focus on first-tier and new first-tier cities, provi
-
-
Pingshan joins hands with Fosun Pharma for biopharmaceuticals
2023-07-28
On 27 July 2023, the People’s Government of Pingshan District and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. signed a strategic cooperation framework agreement in Shanghai.According to the agreement, both sides will engage in long-term and comprehensive strategic cooperation, gathering innovative resources, cultivating and strengthening the b
-
-
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
2023-07-27
·HANQUYOUis the China-developed biosimilar with the mostmarketing approvals, covering41 countries and regions·Thelaunch ofHANQUYOUkicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies·Henlius will continue to expand its overseas footprint and accelerate the delivery of
-
-
Henlius completed the phase 1/2 clinical trial of HLX04-O for the treatment of Ophthalmic Diseases
2023-07-26
Shanghai, China, 26 July 2023 - Shanghai Henlius Biotech, Inc. (2696.HK) announced a phase 1/2 clinical trial of HLX04-O, a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the company and Essex, has been completed in patients with wet age-related macular degeneration (wAMD). The results of this study demonstrated the good safety&
-
-
New Exhibition | “KENGO KUMA: Architecture for the Five Senses” to Officially Open To Public on 21 July!
2023-07-20
On 20 July 2023,Kengo Kuma’s latest solo exhibition,“Architecture for the Five Senses”officially opened at Fosun Foundation (Shanghai)Based on the new concept of "Architecture for the Five Senses”introduced by the world-renowned architect Kengo Kuma,visitors can explore the new form of future architecturethrough the human senses: sight, hearing, touch, smell&
-
-
Emerging Visionaries Hosts its First National Summit & Ceremony After an Upgrade
2023-07-12
On 11 July 2023,Emerging Visionaries National Summit & Ceremony was held in Shanghai Jiulong Model Middle School. Under the guidance of Shanghai People's Association for Friendship with Foreign Countries (SPAFFC), the event was hosted by Prudential Financial, Inc., Fosun Foundation, Pramerica Fosun Life Insurance and Fosun Trade, and organized
-
-
China's NMPA Accepts Fosun Pharma’s BLA for Innovative Botulinum Toxin Product DAXXIFY® for the Treatment of Cervical Dystonia
2023-07-12
(7 July 2023, Shanghai, China) On 7 July, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(“Fosun Pharma”; stock code: 600196.SH, 02196.HK), a global innovation-driven pharmaceutical and healthcare industry group, announced that the Biologics License Application (“BLA”) for DAXXIFY®(DaxibotulinumtoxinA for injection) for the treatment of cervical dyst